Stimulant Use for ADHD in a Cardiac Transplant Recipient: A Case Report

Abstract Introduction Methylphenidate is a central nervous system stimulant used as first-line treatment for attention-deficit/hyperactivity disorder (ADHD). CNS use associated with increased risk of cardiovascular events such resting heart rate and blood pressure, sudden cardiac death, arrhythmia, stroke. Its safety profile in recipients transplants unknown, more research warranted to determine the adverse due medication this population. Methods Clinical case report, n=1 Results/Clinical Case A 19-year-old female history restrictive cardiomyopathy, arrest, orthotopic transplant has been treated methylphenidate ADHD approximately 2 years without incident. The patient was diagnosed between ages 8 10 historically medication. At age 13, she experienced arrest after volleyball game 4–6 minutes pulselessness. She successfully resuscitated underwent defibrillator placement. It concluded that had cardiomyopathy undetected at birth, leading need transplantation 16. After her patient’s memory cognition worsened, 1 year transplant, prescribed amantadine. remained untreated until 1.5 which time neuropsychological testing showed findings consistent attention deficit disorder, restarted on Her cardiologist psychiatrist have collaborated ongoing 40 mg daily monitoring symptom response stability. Because previously stable many years, it reasonable conclude did not lead arrest. reports helpful improving functioning college student, through reduction symptoms. pressure remain within an acceptable range any date while taking methylphenidate. Conclusion This sheds light potential treat ADHD. Although careful evaluation factors must be undertaken cooperation cardiology other specialists, role exists safe medications Funding No